In This Article:
Mesa Laboratories (NASDAQ:MLAB) Second Quarter 2025 Results
Key Financial Results
-
Revenue: US$57.8m (up 8.8% from 2Q 2024).
-
Net income: US$3.43m (up from US$1.23m loss in 2Q 2024).
-
Profit margin: 5.9% (up from net loss in 2Q 2024).
-
EPS: US$0.63 (up from US$0.23 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mesa Laboratories EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates significantly.
Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with Mesa Laboratories.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.